
    
      This is a randomized, multi-center, open-label Phase II clinical trial to determine the
      efficacy of combined plasma exchange (PEX), rituximab, and conventional corticosteroid
      administration, in comparison to corticosteroids alone, among patients with acute IPF
      exacerbations.
    
  